FibroBiologics/$FBLG
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About FibroBiologics
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Ticker
$FBLG
Sector
Primary listing
Employees
15
Headquarters
Website
FibroBiologics Metrics
BasicAdvanced
$18M
-
-$0.42
-0.67
-
Price and volume
Market cap
$18M
Beta
-0.67
52-week high
$1.53
52-week low
$0.22
Average daily volume
1.2M
Financial strength
Current ratio
3.609
Quick ratio
2.782
Long term debt to equity
27.68
Total debt to equity
39.149
Interest coverage (TTM)
-81.61%
Profitability
EBITDA (TTM)
-16.405
Management effectiveness
Return on assets (TTM)
-79.85%
Return on equity (TTM)
-419.44%
Valuation
Price to book
2.81
Price to tangible book (TTM)
2.81
Price to free cash flow (TTM)
-0.698
Free cash flow yield (TTM)
-143.17%
Free cash flow per share (TTM)
-0.373
Growth
Earnings per share change (TTM)
22.98%
3-year earnings per share growth (CAGR)
32.03%
What the Analysts think about FibroBiologics
Analyst ratings (Buy, Hold, Sell) for FibroBiologics stock.
FibroBiologics Financial Performance
Revenues and expenses
FibroBiologics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for FibroBiologics stock?
FibroBiologics (FBLG) has a market cap of $18M as of March 19, 2026.
What is the P/E ratio for FibroBiologics stock?
The price to earnings (P/E) ratio for FibroBiologics (FBLG) stock is 0 as of March 19, 2026.
Does FibroBiologics stock pay dividends?
No, FibroBiologics (FBLG) stock does not pay dividends to its shareholders as of March 19, 2026.
When is the next FibroBiologics dividend payment date?
FibroBiologics (FBLG) stock does not pay dividends to its shareholders.
What is the beta indicator for FibroBiologics?
FibroBiologics (FBLG) has a beta rating of -0.67. This means that it has an inverse relation to market volatility.